Clinical trial
A Phase I Trial of a LTK63 Adjuvated Tuberculosis Nasal Subunit Vaccine…
NCT00440544 · St George's, University of London, Other · Terminated
Key facts
| NCT number | NCT00440544 |
|---|---|
| Title | A Phase I Trial of a LTK63 Adjuvated Tuberculosis Nasal Subunit Vaccine (Ag85B-ESAT6) |
| Official title | A Phase I Trial of the Safety and Immunogenicity of an Adjuvated TB Subunit Vaccine (Ag85B-ESAT6 + LTK63) Administered at 0 and 2 Months |
| Acronym | TMUVA-01 |
| Lead sponsor | St George's, University of London, Other |
| Collaborators | Statens Serum Institut Novartis Vaccines Industry European Union |
| Status | Terminated |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Tuberculosis |
| Intervention type | Biological |
| Interventions | Ag85B-ESAT6 fusion protein H1 |
| Enrollment | 9 |
| Start date | Jan 1, 2007 |
| Primary completion | Nov 1, 2007 |
| Completion | Feb 1, 2008 |
| First posted | Feb 27, 2007 |
| Last update posted | Nov 3, 2008 |
| Countries | United Kingdom |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: